Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Xenpozyme Approved By FDA As First Disease-Specific Treatment For ASMD

Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinaseParis, August 31, 2022. The U.S.
byBenzinga Newsdesk
August 31, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase

Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Xenpozyme is the first therapy indicated specifically for the treatment of ASMD, and is currently the only approved treatment for this disease.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Significant Six Flags Shareholder Land & Buildings Issues Statement On The Company’s Proposed Merger With Cedar Fair; Intends To Vote Against The Merger And Explore All Options To Realize Full Value For Shareholders

By Benzinga Newsdesk
November 2, 2:28 PM
Significant Six Flags Shareholder Land & Buildings Issues Statement on the Company's Proposed Merger with Cedar FairBelieves Proposed Deal Does Not Maximize Value for All Shareholders and that Monetizing Six Flags'

FUN